Aveanna Healthcare (NASDAQ:AVAH) Stock Rating Upgraded by Raymond James Financial

Aveanna Healthcare (NASDAQ:AVAH) was upgraded by investment analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a research note issued on Friday, Marketbeat reports. The firm currently has a $13.00 price target on the stock. Raymond James Financial’s price objective would indicate a potential upside of 97.72% from the stock’s previous close.

A number of other research firms have also weighed in on AVAH. William Blair assumed coverage on shares of Aveanna Healthcare in a research note on Monday, December 8th. They issued an “outperform” rating on the stock. UBS Group lifted their price objective on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. Barclays boosted their price objective on Aveanna Healthcare from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Royal Bank Of Canada raised their target price on Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 15th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.06.

Aveanna Healthcare Price Performance

Shares of NASDAQ AVAH traded up $0.24 during mid-day trading on Friday, reaching $6.58. The company’s stock had a trading volume of 622,390 shares, compared to its average volume of 1,191,118. The stock has a market capitalization of $1.37 billion, a P/E ratio of 18.26 and a beta of 2.07. Aveanna Healthcare has a 1-year low of $3.73 and a 1-year high of $10.32. The stock has a 50-day moving average of $7.88 and a two-hundred day moving average of $8.50. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.

Insider Buying and Selling

In other news, CEO Jeff Shaner sold 173,225 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $1,248,952.25. Following the transaction, the chief executive officer owned 2,650,892 shares of the company’s stock, valued at $19,112,931.32. This represents a 6.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick A. Cunningham sold 18,436 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $132,923.56. Following the transaction, the insider owned 337,755 shares of the company’s stock, valued at approximately $2,435,213.55. This represents a 5.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 998,595 shares of company stock valued at $7,567,770. 7.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aveanna Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in AVAH. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Aveanna Healthcare by 252.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after acquiring an additional 2,400 shares during the last quarter. Invesco Ltd. raised its position in Aveanna Healthcare by 1,001.5% in the fourth quarter. Invesco Ltd. now owns 360,464 shares of the company’s stock valued at $2,945,000 after purchasing an additional 327,738 shares during the period. Mackenzie Financial Corp raised its position in Aveanna Healthcare by 12.7% in the fourth quarter. Mackenzie Financial Corp now owns 216,200 shares of the company’s stock valued at $1,810,000 after purchasing an additional 24,447 shares during the period. Zimmer Partners LP acquired a new position in Aveanna Healthcare during the fourth quarter worth $6,189,000. Finally, Voloridge Investment Management LLC purchased a new position in shares of Aveanna Healthcare during the fourth quarter worth $1,915,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

Key Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q4 results beat expectations — Aveanna reported a strong Q4 with EPS well above estimates and revenue that topped Street forecasts, driven by outsized year‑over‑year revenue growth. This demonstrates continued demand in its home‑health business. Read More.
• Positive Sentiment: Solid top‑line growth — revenue rose roughly in the high‑teens/20s percent year over year (company reported ~27.4% YoY increase), and several outlets note revenue and key metrics outperformed analyst estimates for the quarter. That supports the company’s growth narrative in medically complex home care. Read More.
• Neutral Sentiment: Earnings call/transcript available — management provided color on segment performance, margin drivers and operational cadence; read the transcript for details that could inform whether guidance is conservative or indicative of a trend. Read More.
• Neutral Sentiment: Short‑interest data reported in some feeds appears inconsistent/invalid (zero shares / NaN changes); current published short‑interest figures are not providing a clear signal on bearish positioning. (Data flagged by multiple services.)
• Negative Sentiment: Fiscal‑2026 guidance disappointed — management’s revenue outlook and growth guidance came in below consensus, and headlines focus on the guidance miss as the primary reason for the intraday sell‑off. That guidance shortfall is weighing on the stock despite the quarter’s beat. Read More.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.